Free Trial
NASDAQ:CDTX

Cidara Therapeutics Q4 2024 Earnings Report

Cidara Therapeutics logo
$21.69 -0.06 (-0.28%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$21.64 -0.05 (-0.23%)
As of 05/2/2025 06:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cidara Therapeutics EPS Results

Actual EPS
-$5.38
Consensus EPS
-$5.28
Beat/Miss
Missed by -$0.10
One Year Ago EPS
N/A

Cidara Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cidara Therapeutics Announcement Details

Quarter
Q4 2024
Time
After Market Closes
Conference Call Date
Thursday, March 6, 2025
Conference Call Time
8:00AM ET

Upcoming Earnings

Cidara Therapeutics' Q1 2025 earnings is scheduled for Thursday, May 8, 2025, with a conference call scheduled at 5:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Cidara Therapeutics Earnings Headlines

Cidara Therapeutics appoints new CMO and SVP
Elon Musk is all in on these robots …
Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang said, "The ChatGPT moment for robotics is right around the corner." In fact, I believe these robots could impact 65 million Americans lives — this year. And one stock — currently priced around $7 — could be the biggest winner.
See More Cidara Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cidara Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cidara Therapeutics and other key companies, straight to your email.

About Cidara Therapeutics

Cidara Therapeutics (NASDAQ:CDTX), a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

View Cidara Therapeutics Profile

More Earnings Resources from MarketBeat